因塞特医疗 INCY 深 沪
等待开盘 06-03 09:30:00 美东时间
92.265
-3.325
-3.48%
华盛通- 最 高103.01
- 今 开94.70
- 成交量 147.63万股
- 最 低 92.25
- 昨 收 95.59
- 总市值 2048.28万
- 52周最高 112.29
- 市盈率 静 21.60
- 换手率 665.02%
- 52周最低 66.7401
- 委 比 17.56%
- 总股本 0.00亿
- 历史最高 153.15
- 量 比 1.14
- 振 幅 11.26%
- 历史最低 1.10
- 每 手 1
- 风险率 12.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多A Glimpse Into The Expert Outlook On Incyte Through 13 Analysts
Throughout the last three months, 13 analysts have evaluated Incyte (NASDAQ:INC...
03-09 20:00
Incyte Sees FY26 Net Product Revenue Of $4.77B-$4.94B
2026 Financial GuidanceIncyte's guidance for the fiscal year 2026 is summarized below. Total net product revenue guidance of $4,770 to $4,940 million comprises: Jakafi net product revenue of $3,220 to $3,270 million and
02-10 20:03
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
01-12 18:47
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
Incyte reported positive results from a trial of tafasitamab as a first-line treatment for adults with DLBCL. No new safety issues were seen.
01-06 00:59
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms
Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook.
2025-10-29 02:44
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
2025-10-28 19:11
Incyte Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
In the preceding three months, 6 analysts have released ratings for Incyte (NAS...
2025-03-11 22:00
JMP Securities Reiterates Market Perform on Incyte
JMP Securities analyst Reni Benjamin reiterates Incyte (NASDAQ:INCY) with a Market Perform.
2024-09-18 00:22
Guggenheim Maintains Buy on Incyte, Raises Price Target to $92
Guggenheim analyst Michael Schmidt maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $86 to $92.
2024-09-17 00:45
Reported Saturday, Incyte Unveils Results For CDK2 Inhibitor INCB123667 In Advanced Solid Tumors, Ovarian Cancer Among Highlighted
New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event These results build upon safety and tolerability data presented earlier today during a mini-oral presentation at
2024-09-16 15:58
